原发性高草酸尿症:从临床试验到真实世界数据及在研疗法
本文综述原发性高草酸尿症(PH)的病理生理、诊断与治疗进展,重点介绍RNA干扰疗法(如lumasiran、nedosiran)在临床试验和真实世界中降低尿草酸、稳定肾功能的作用,并讨论孤立肾移植、基因编辑等新兴策略及诊断延迟、药物可及性等挑战。
要点
- Lumasiran抑制乙醇酸氧化酶,在PH1关键试验和多数真实世界患者中持续降低尿草酸、稳定肾功能并减少肾钙质沉着。
- Nedosiran靶向乳酸脱氢酶A,在PH1显示应用前景,但在PH2和PH3疗效有限。
- 在RNA干扰治疗下,孤立肾移植已成功实施,为终末期肾病合并草酸代谢异常提供新策略。
核心结论
- RNA干扰疗法通过GalNAc偶联递送靶向沉默肝脏草酸合成相关酶,已革新PH治疗格局,但PH2/PH3疗效有限且诊断延迟与药物可及性仍是全球挑战。
研究设计与样本
- 本文为小型综述,总结PH病理生理、诊断和治疗的最新里程碑,涵盖关键试验与真实世界数据。
主要发现
- Lumasiran在PH1关键试验和多数真实世界患者中显示持续降低尿草酸、稳定肾功能并减少肾钙质沉着。
- Nedosiran靶向乳酸脱氢酶A,在PH1显示前景,但在PH2和PH3疗效有限。
- 在RNA干扰治疗下,孤立肾移植已成功实施,可控制草酸产生并管理肾衰竭。
- 新兴疗法包括基因编辑、mRNA替代和药物重定位策略,旨在拓宽治疗选择和可及性。
- 尽管治疗进步,诊断延迟仍存在,且评估多身体隔室草酸储备在临床上仍具挑战。
临床怎么用
- 对PH1患者,可考虑使用lumasiran以持续降低尿草酸并稳定肾功能。
- 在RNA干扰治疗控制草酸产生的条件下,孤立肾移植可作为管理肾衰竭的策略。
- 需提高对PH的认识并推行标准化筛查以减少诊断延迟,同时关注昂贵疗法的公平可及性。
局限性
- PH2和PH3的疗效有限,可能与肝外草酸代谢和/或尚未识别的代谢机制有关。
- 多身体隔室草酸储备的评估在临床上仍具挑战,影响个体化移植策略的制定。
- 确保昂贵疗法的公平可及是全球医疗保健挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary hyperoxalurias (PHs) are a group of rare autosomal recessive disorders of glyoxylate metabolism leading to excessive oxalate production, recurrent nephrolithiasis, nephrocalcinosis, and progression to kidney failure with systemic oxalosis in the most severe forms. Until recently, treatment options were limited to conservative measures and double liver/kidney transplantation. The advent of small interfering RNA therapies has revolutionized the field by enabling targeted hepatic enzyme silencing via GalNAc-conjugated delivery involved in oxalate synthesis. Lumasiran, approved for PH1, inhibits glycolate oxidase and has demonstrated sustained reductions in urinary oxalate, stabilization of renal function, and reduced nephrocalcinosis in pivotal trials and in most patients in real life. Nedosiran, targeting lactate dehydrogenase A, shows promise for PH1. Efficacy in PH2 and PH3 remains limited, perhaps due to extrahepatic oxalate metabolism and/or other as-yet unidentified metabolic mechanisms. Isolated kidney transplantation under RNA interference therapy has been successful, offering a promising strategy to manage kidney failure while controlling oxalate production. Emerging therapies include gene editing, mRNA replacement, and drug repurposing strategies, aiming to broaden treatment options, and accessibility. Despite advances in treatment, delayed diagnosis persists, highlighting the need for greater awareness and standardized screening. Assessing oxalate stores in multiple body compartments also remains clinically challenging but is needed to improve global patients' management, notably for personalizing transplantation strategies. In addition, ensuring equitable access to expensive therapies presents a worldwide health care challenge. This mini review summarizes recent milestones in PH pathophysiology, diagnostics, and therapeutics, emphasizing the transformative impact of RNA interference therapies and future directions in managing this ultrarare but devastating kidney disease.
引用
- Bacchetta J, Acquaviva-Bourdain C, Abid N, et al. Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies. Kidney Int. 2026. PMID: 41579959. doi:10.1016/j.kint.2025.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。